SYGNIS AG signs distribution agreement for Switzerland

LABGENE Scientific to sell next generation sequencing and single cell analysis applications

18-Sep-2015 - Germany

SYGNIS AG announced that it has signed a distribution agreement with LABGENE Scientific for the commercialization of SYGNIS’ proprietary product portfolio in Switzerland.

Under the terms of the agreement, SYGNIS has granted LABGENE Scientific the rights to promote, market and sell all existing as well as future product lines to scientists working in genomics, proteomics and diagnostics in Switzerland. These product lines cover the Company’s TruePrime™ products for primer-free whole genome amplification as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA including the newly launched SunScript™ One Step Reverse Transcriptase (RT)-PCR Kit for parallel transcription and amplification of genomic information.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances